IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the vacancy resulting from the resignation of a former director in November of this year. Dr. Lo will act as the chairperson of the audit committee and the member of the compensation committee and the nomination and corporate governan
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13G - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
20-F - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
- The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD ("SKATBT-A3"), which measures the effectiveness of the treatment on the patient's overall body and neurodevelopmental conditions, showed a mean percentage improvement of 37% in the second efficacy trial based on the scoring system of SKATBT-A3. - The first efficacy trial using personalized TCM formulae have shown a mean percentage improvement of 30% in ADHD symptoms and a mean percentage improvement of 37% in ASD symptoms, based on the scoring systems under the Vanderbilt ADHD Diagnostic Parent Rating Scale ("VADRS") and the Autism Treatment Evaluation Checklist ("ATEC"), respectively, after 3 months of treatment. - The ongoin
Regencell Bioscience Holdings Limited (NASDAQ:RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patients) 90.2 83.8 87.5 Testing negative in 6 days (% of patients) 23.5 43.5 29.7 Recovery period for patients who took RGC-COV19TM within 3 days of sy
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman and CEO, made purchases of ordinary shares in Regencell ("Ordinary Shares") totaling $5.03 million. Based on his Schedule 13D filings with the U.S. Securities and Exchange Commission (the "SEC") between July 27, 2021 and May 16, 2022, Mr. Au used an aggregate of $5.03 million of his personal funds to
36 out of 37 COVID-19 patients treated in the trial, representing approximately 97.3% of the patients, reported they had all symptoms eliminated within the 6-day treatment period save for loss or reduced sense of taste and smell ("Sensory Dysfunction") and occasional cough. The highest number of different symptoms reported for any one individual was 14. 15 out of the 36 patients experienced Sensory Dysfunction prior to receiving treatment. Among those 15 patients, 5 recovered their sensory functions while the remaining 10 showed improvements at the end of the 6-day treatment period. 31 out of 37 COVID-19 patients, representing approximately 83.8% of patients, reported the elimination o
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the vacancy resulting from the resignation of a former director in November of this year. Dr. Lo will act as the chairperson of the audit committee and the member of the compensation committee and the nomination and corporate governan
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman & CEO, made Ordinary Share purchases of Regencell ("Ordinary Shares") totaling $1,125,807. As per the Schedule 13D filed with the SEC on November 22, 2021, Mr. Au has used an aggregate of $1,125,807 of his personal funds to purchase Ordinary Shares made through the Reporting Persons' Rule 10b-18 Plan. According to the 10b-18 Plan, fo
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective December 1, 2021). MSCI Inc., a leading provider of research-based indexes and analytics, announced Regencell's addition on November 11, 2021, following results of their semi-annual index review. Launched on December 1, 2010, the
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), today announced that Regencell Bioscience Limited ("Regencell HK"), the Company's wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited ("Honor Epic"). The joint venture ("JV") is expected to offer COVID-19 ("COVID") related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. As COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since March 2020, Mr. Sik-Kee A
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder ("ADHD") and Autism Spectrum Disorder ("ASD"), today announced that the underwriter of its initial public offering (the "Offering") had exercised its option to purchase 325,000 additional ordinary shares at the public offering price of US$9.50 per share to cover over-allotments. Gross proceeds from the Offering, including proceeds from the exercise of the over-
Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company today released a letter from Yat-Gai Au, Founder and Chief Executive Officer of the Company. Dear Shareholders: As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyond. For those who are new to Regencell, the Company focuses on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specificall